H.C. Wainwright analyst Debjit Chattopadhyay said the CHMP confirming its negative opinion for a Conditional Marketing Application for Sarepta's eteplirsen was widely anticipated given the prior negative CHMP opinion disclosed on June 1. While a CHMP nod would have represented further upside on the commercial front, the company's calendar is "chalk full of value drivers" over the next 12 to 18 months, said Chattopadhyay, who remains a buyer on the CHMP-related pullback. He keeps a Buy rating and $267 price target on Sarepta shares, which are down 2% to $149.60 in late morning trading.